Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $7000.0.

  • Compass Therapeutics' Capital Expenditures fell 8409.09% to $7000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $25000.0, marking a year-over-year decrease of 5283.02%. This contributed to the annual value of $44000.0 for FY2024, which is 4666.67% up from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Capital Expenditures is $7000.0, which was down 8409.09% from $18000.0 recorded in Q1 2025.
  • Compass Therapeutics' 5-year Capital Expenditures high stood at $44000.0 for Q3 2024, and its period low was $7000.0 during Q3 2025.
  • Over the past 3 years, Compass Therapeutics' median Capital Expenditures value was $10500.0 (recorded in 2023), while the average stood at $16500.0.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 34000.0% in 2024, then crashed by 8409.09% in 2025.
  • Over the past 3 years, Compass Therapeutics' Capital Expenditures (Quarter) stood at $9000.0 in 2023, then surged by 388.89% to $44000.0 in 2024, then plummeted by 84.09% to $7000.0 in 2025.
  • Its Capital Expenditures was $7000.0 in Q3 2025, compared to $18000.0 in Q1 2025 and $44000.0 in Q3 2024.